Scientists at Purdue University have developed a urine test for early-stage Parkinson’s disease. The technology involves isolating extracellular vesicles of neural origin from urine samples and then assessing the proteins within the vesicles to…
Continue Reading
As the healthcare industry strives toward precision medicine, it will be essential for care providers to gain an intimate view of a patient’s response to treatment to determine its impact on their quality of…
Continue Reading
What You Should Know: Somavedic Technologies (Inc.), makers of the scientifically-studied sleep & well-tech device by the same name, launches Attune Health Mobile App, an AI-enabled, biomarker analysis, offering 100% contactless solution that enables…
Continue Reading
Researchers at the Hubrecht Institute in the Netherlands have developed a biobank of cancer organoids using tissue samples obtained from head and neck cancer patients. So far, the team used the biobank to validate…
Continue Reading
Lifeforce, a personalized healthcare platform based on a telehealth model, completed a $12 million Series A funding round co-led by M13 and Peterson Ventures. Ridgeline Ventures, Rosecliff Ventures and Seaside Ventures also participated in the…
Continue Reading
Roche UK and digital health technology company Nye Health have announced a partnership aiming to co-create digital solutions that learn, personalise and adapt to patients’ needs outside of a hospital or traditional clinical setting.Co-created…
Continue Reading
ML tool predicts Parkinson’s onsetA research team from the University of New South Wales, together with their collaborators from Boston University, has come up with an AI tool that could be potentially used to…
Continue Reading
Background: Depressive and manic episodes within bipolar disorder (BD) and major depressive disorder (MDD) involve altered mood, sleep, and activity, alongside physiological alterations wearables can capture. Objective: Firstly, we explored whether physiological wearable data…
Continue Reading
GrayMatters Health, a medtech company based in Israel, has developed Prism for PTSD, a self-neuromodulation therapy. The company has identified what they describe as brain-mechanism-specific biomarkers for certain mental disorders. These involve combining fMRI…
Continue Reading
Major depressive disorder (MDD) is associated with circadian rhythm disruption. Yet, no circadian rhythm biomarkers have been clinically validated for assessing antidepressant response. In this study, 40 participants with MDD provided actigraphy data using…
Continue Reading
